Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
Non-HIV-infected
100%
Acute Focal Bacterial Nephritis
100%
Squamous Cell Cancer
100%
HIV Patients
100%
Lactams
100%
Retrospective Cohort Study
100%
Quinolones
100%
Therapeutic Failure
40%
β-lactam Antibiotics
40%
Route of Administration
20%
Antibiotic Regimen
20%
Klebsiella Pneumoniae (K. pneumoniae)
20%
Intravenous Antibiotics
20%
Spain
20%
Codification
20%
Barcelona
20%
Escherichia Coli
20%
Treatment Duration
20%
Abscess
20%
Adverse Events
20%
Phlebitis
20%
Single-center Study
20%
Isolated Microorganisms
20%
Inclusion Criteria
20%
January 2017
20%
Hebron
20%
Catheter-related Bacteremia
20%
Ciprofloxacin
20%
Human Papillomavirus DNA
15%
Highly Active Antiretroviral Therapy (HAART)
15%
Human Papillomavirus Types
15%
Positive Samples
15%
DNA Genotyping
7%
Conventional Vaccine
7%
Formaldehyde
7%
HPV16
7%
Etiological Agents
7%
Multiplex PCR (mPCR)
7%
Uncommon Diseases
7%
Biopsy Specimen
7%
Paraffin-embedded Specimens
7%
Human Papillomavirus 33
7%
Tertiary Hospital
7%
Anal Canal
7%
Papillomavirus Infections
7%
Human Papillomavirus 52
7%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Lactam
100%
Nephritis
100%
Quinolone Derivative
100%
Beta Lactam Antibiotic
40%
Route of Administration
20%
Antibiotics
20%
Abscess
20%
Klebsiella pneumoniae
20%
Phlebitis
20%
Escherichia coli
20%
Adverse Event
20%
Ciprofloxacin
20%
Microorganism
20%
Bloodstream Infection
20%
Medicine and Dentistry
Lactam
100%
Quinolone Derivative
100%
Retrospective Cohort Study
100%
Nephritic Syndrome
100%
β-Lactam antibiotic
40%
Abscess
20%
Escherichia coli
20%
Adverse Event
20%
Antibiotics
20%
Treatment Duration
20%
Ciprofloxacin
20%
Bloodstream Infection
20%
Diagnosis
20%
Klebsiella pneumoniae
20%
Phlebitis
20%
